Strata Critical Medical

SRTA

Medical - Care Facilities · Healthcare

Price

$6.24

+0.28 (+4.70%)

Market Cap

$539.9M

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Good

Track this stock — start free trial

Share count rising — dilution

+17.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 70.1M (2021) → 82.5M (2025)

Winston Score History

The full picture

Strata Critical Medical, Inc. (ticker: SRTA) does not appear to match the industry and sector data provided — a medical company classified under Airlines, Airports & Air Services is an unusual combination, and reliable public information on this specific company is limited. Based on the available data, this appears to be a small-cap company with roughly $500 million in market value operating in the industrials space, though the exact nature of its products and customers is unclear.

What the financials do reveal is that the company earns a modest gross margin of around 20%, while losing money at the operating level, with a negative operating margin of 6% and a negative return on invested capital. This suggests the business is still in a growth or turnaround phase and has not yet reached profitability. The main risk facing the company is its current inability to cover operating costs, which could pressure cash reserves and require additional financing if losses continue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+2.4% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-160.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$3M/ year

→ Flat (-4% vs prior year)

1.5% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

48.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$23M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Strata Critical Medical is growing revenue at 2% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

21.0%

Thin — 21.0% gross margin

Profit after running costs

Operating Margin

-7.5%

Losing money on operations — -7.5%

Return on the money invested

ROCE

-7.3%

Weak — -7.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+0.6%

Nearly flat sales (+0.6% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

-77%

Weak — only -77% of profit becomes cash

Spare cash per sale

FCF Margin

-17.2%

Burning cash (-17.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

12.5x

Attractive valuation — P/E 12.5

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial